BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

OriGene Technologies Announces the Release Specificity-Verified UltraMAB(TM) Antibodies


3/21/2012 9:00:29 AM

ROCKVILLE, Md., March 20, 2012 /PRNewswire/ -- OriGene Technologies today announced the release of a new line of ultra specific and extensively validated monoclonal antibodies under the UltraMAB brand. UltraMAB Antibodies are a collection of monoclonal antibodies which are exclusively developed by OriGene for IHC applications and are the industry's only antibody products available on the market that have been validated with the Company's breakthrough 10K High Density Protein Microarray Technology. OriGene's 10K High Density Protein Microarray Platform enables the screening of candidate antibodies against greater than 10,000 human proteins to identify the most specific monoclonal antibodies for IHC applications.

"High-specificity is the pre-requisite for any IHC antibody because IHC detection relies on only one antibody against a complex tissue sample. Through the use of novel and proprietary technologies such as our 10K High-Density Protein Microarray Platform, OriGene has dramatically improved the specificity of antibodies available to the global market place. By validating all UltraMAB antibodies against our 10K High-Density Protein Microarray Platform, the market now has access to one of the industry's most significant tools for IHC detection and determination of accurate results," said Dr. Wei-Wu He, Ph.D., CEO & Chairman, OriGene Technologies.

Each UltraMAB is validated for IHC and for immunoassay analysis, and determined to have no cross-reactivity with other human proteins other than the antibody's intended target protein as determined by OriGene's 10K High Density Protein Microarray Platform. Consequently, each UltraMAB is quality control verified, guaranteeing superior performance for IHC applications, where specificity-verification and the highest quality antibodies are critical for accurate detection.

Detailed information about the UltraMAB Antibodies is available at www.origene.com/UltraMAB, where customers can learn more about OriGene's unique approach to monoclonal antibody development and contact the company's representatives to explore collaborative opportunities.

OriGene will present the new line of UltraMAB Antibodies at the USCAP 2012 Annual Meeting in Vancouver, CA; March 17-23rd Booth # 827. To register for the company's free seminar presentation on UltraMAB please visit www.origene.com.

About OriGene Technologies

OriGene Technologies, Inc., is a biosciences company dedicated to develop gene centric innovative products and services to improve the quality of healthcare diagnostics and treatments. The Company's broadest collection of gene based products and services are important tools to accelerate the discovery of new diagnostics and drug treatments for better patient care. OriGene has one of the largest scale antibody production and highest quality process facilities in the world. For more information, visit www.OriGene.com.

SOURCE OriGene Technologies



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES